$74.50
0.49% yesterday
Nasdaq, Dec 24, 07:00 pm CET
ISIN
US4364401012
Symbol
HOLX

Hologic Stock price

$74.50
-0.26 0.35% 1M
+9.67 14.92% 6M
+2.41 3.34% YTD
+1.82 2.50% 1Y
-1.01 1.34% 3Y
-0.27 0.36% 5Y
+35.42 90.63% 10Y
+54.77 277.60% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
-0.37 0.49%

New AI Insights on Hologic Insights AI Insights on Hologic

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$16.6b
Enterprise Value
$16.9b
Net debt
$317.7m
Cash
$2.2b
Shares outstanding
222.6m
Valuation (TTM | estimate)
P/E
29.8 | 16.0
P/S
4.1 | 3.8
EV/Sales
4.1 | 3.9
EV/FCF
18.7
P/B
3.3
Financial Health
Equity Ratio
56.0%
Return on Equity
11.2%
ROCE
13.3%
ROIC
15.7%
Debt/Equity
0.5
Financials (TTM | estimate)
Revenue
$4.1b | $4.4b
EBITDA
$1.1b | $1.4b
EBIT
$1.1b | $1.3b
Net Income
$565.7m | $1.0b
Free Cash Flow
$904.7m
Growth (TTM | estimate)
Revenue
1.7% | 6.7%
EBITDA
8.4% | 32.7%
EBIT
10.1% | 22.6%
Net Income
-28.3% | 82.7%
Free Cash Flow
-21.0%
Margin (TTM | estimate)
Gross
56.4%
EBITDA
26.4% | 32.8%
EBIT
26.1%
Net
13.8% | 23.6%
Free Cash Flow
22.1%
More
EPS
$2.5
FCF per Share
$4.1
Short interest
2.6%
Employees
7k
Rev per Employee
$580.0k
Show more

Is Hologic a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Hologic Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Hologic forecast:

7x Buy
28%
18x Hold
72%

Analyst Opinions

25 Analysts have issued a Hologic forecast:

Buy
28%
Hold
72%

Financial data from Hologic

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
4,101 4,101
2% 2%
100%
- Direct Costs 1,790 1,790
1% 1%
44%
2,311 2,311
2% 2%
56%
- Selling and Administrative Expenses 994 994
0% 0%
24%
- Research and Development Expense 234 234
14% 14%
6%
1,083 1,083
8% 8%
26%
- Depreciation and Amortization 14 14
51% 51%
0%
EBIT (Operating Income) EBIT 1,069 1,069
10% 10%
26%
Net Profit 566 566
28% 28%
14%

In millions USD.

Don't miss a Thing! We will send you all news about Hologic directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Hologic Stock News

Neutral
Business Wire
9 days ago
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #AI--Hologic's AI-Powered Mammography Technology Flagged a Third of Breast Cancer Cases Initially Interpreted as Negative in Study of 7,500 Screening Exams.
Neutral
Business Wire
23 days ago
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #holx--New Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test.
Neutral
Business Wire
about one month ago
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #AI--New Clinical Evidence on Hologic's AI-Powered Mammography Solutions Will Be Unveiled at RSNA.
More Hologic News

Company Profile

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following business segments: Breast Health, Diagnostics, Medical Aesthetics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a broad portfolio of breast imaging and related products and accessories, including digital mammography systems, computer-aided detection, for mammography and minimally invasive breast biopsy devices, breast biopsy site markers, and breast biopsy guidance systems. The Diagnostics segment comprises Aptima family of Assays, target capture/nucleic acid extraction techonolgy, transcription-mediated amplification technology, hybridization protection assay and dual kinetic assat technologies, instrumentation, and Invader Chemistry Platform. The Medical Aesthetics segment offers SculpSure; PicoSure, MedLite, and RevLite; and MonaLisa Touch. The GYN Surgical segment encompasses the NovaSure Endometrial Ablation System and the MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment covers the discovery and horizon X-ray bone densitometry system, an ultrasound-based osteoporosis assessment product, and Fluoroscan mini C-arm imaging products. The company was founded by S. David Ellenbogen and Jay A. Stein in 1986 and is headquartered in Marlborough, MA.

Head office United States
CEO Stephen MacMillan
Employees 7,063
Founded 1985
Website www.hologic.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today